Three ESMO Datasets Back Darovasertib as Foundational Uveal Melanoma Therapy
IDYA sits 25% above its 52-week low of $26.81.
Summary
IDEAYA and partner Servier presented data from three clinical trials at ESMO 2026 that they say support darovasertib as a foundational therapy across the uveal melanoma treatment journey. The headline gives no efficacy numbers, response rates, or trial names, so the actual strength of the data is not yet clear from this release. This is the lead asset for a company with a $1.24B cash position and an NDA submission guided for H2 2026, so any incremental clinical validation matters for the regulatory case. The stock is a clinical-stage biotech where the darovasertib program drives the thesis; positive readouts reinforce the filing path, weak ones would undercut it. The H2 2026 NDA submission is the next hard milestone to track.
At the time of this announcement, IDYA was trading at $33.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.2B. The 52-week trading range was $26.81 to $42.68. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.